Clinical Trials | A Phase 3 Randomized Study Comparing Investigational Medicine Combinations and Investigator’s Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants with Relapsed or Refractory Myeloma who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide

The University of Virginia is conducting a clinical research study for adults ages 18 and over who have relapsed or refractory myeloma and have received at least 1 prior line of therapy. The purpose of this study is to compare the effects of investigation medicine combinations with the effects of either the combination of elotuzumab, pomalidomide, and dexamethasone (EPd) or pomalidomide, bortezomib, and dexamethasone (PVd) in treating patients with multiple myeloma, who have not responded to previous treatment. There are 3 study treatment groups in this study which means each person will have an equal chance of being put into Arm A (investigational medicine combination), Arm B (investigational medicine combination), or Arm C (EPd or PVd). You will randomly, or by chance (like flipping a coin), be put into one of the study treatment groups. Study treatment will be administered in 28-day cycles for Arm A, Arm B, and Arm C (EPd). For Arm C (PVd), study treatment will be administered in 21-day cycles. If you receive the investigational medicine combinations, you will receive study treatment for up to 26 cycles total. You are expected to be in this research study for about 5 years depending on how you respond to study treatment. Study-required procedures that are being done beyond your standard of care will be provided at no cost to you. Additional information can be found here: https://clinicaltrials.gov/study/NCT06208150 [email protected]